Trial · NCT07878299
Comparison of Segmental Body Composition Characteristics in Lipedema and Obesity
NCT07878299, Recruiting, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Segmental Body Composition Characteristics in Lipedema and Obesity. Trials, record NCT07878299. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07878299
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Segmental Body Composition Characteristics in Lipedema and Obesity
- NCT number
- NCT07878299
- Status
- Recruiting
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
- Conditions
- Lipedema, Obesity, Body Mass Index, Bioelectrical Impedance Analysis
- Interventions
- Bioelectrical Impedance Analysis, Numeric Rating Scale, Lower Extremity Functional Scale, Short Form-12, Clinical Staging
- First posted
- 2026-10-16
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Ratio of the total fat mass of the two legs to total body fat mass | Baseline | The ratio will be calculated by dividing the sum of the fat mass of both legs by total body fat mass, as measured using bioelectrical impedance analysis. |
| Secondary | Total fat mass | Baseline | Total fat mass will be measured in kilograms using bioelectrical impedance analysis and represents the estimated total amount of fat mass in the body. |
| Secondary | Fat-free body mass | Baseline | Fat-free body mass will be measured in kilograms using bioelectrical impedance analysis and represents total body mass excluding fat mass. |
| Secondary | Total and skeletal muscle mass | Baseline | Total muscle mass and skeletal muscle mass will be measured in kilograms using bioelectrical impedance analysis and represent the estimated amounts of total muscle tissue and skeletal muscle tissue in the body, respectively. |
| Secondary | Total body water | Baseline | Total body water will be measured in kilograms using bioelectrical impedance analysis and represents the estimated total amount of water in the body. |
| Secondary | Visceral fat level | Baseline | Visceral fat level will be assessed using bioelectrical impedance analysis and reported as a device-generated rating reflecting the estimated amount of fat surrounding the internal abdominal organs. |
| Secondary | Leg-to-trunk fat ratio | Baseline | The leg-to-trunk fat ratio will be calculated by dividing the sum of the fat mass of both legs by trunk fat mass, as measured using bioelectrical impedance analysis. |
| Secondary | Leg-to-arm fat ratio | Baseline | The leg-to-arm fat ratio will be calculated by dividing the sum of the fat mass of both legs by the sum of the fat mass of both arms, as measured using bioelectrical impedance analysis. |
| Secondary | Leg muscle-to-fat ratio | Baseline | The leg muscle-to-fat ratio will be calculated by dividing the total muscle mass of both legs by the total fat mass of both legs, as measured using bioelectrical impedance analysis. |
| Secondary | Right-left extremity asymmetry | Baseline | Right-left extremity asymmetry will be assessed by calculating the absolute differences in fat mass and muscle mass between the right and left upper and lower extremities, as measured using bioelectrical impedance analysis. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07878299
GET https://conductscience.org/api/trials/v1/NCT07878299/registered